ArticleOncology letters2019
Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Helicobacter pylori infection promotes the progression of gastric cancer by regulating the expression of DMBT1.World journal of clinical oncology · 2025Article
- Mechanisms underlying the promotion of papillary thyroid carcinoma occurrence and progression by Hashimoto's thyroiditis.Frontiers in endocrinology · 2025Review
- The role of PI3K/AKT signaling pathway in gallbladder carcinoma.American journal of translational research · 2022Review
- No effect of deleted in malignant brain tumors 1 deficiency on chemotherapy induced murine intestinal mucositis.Scientific reports · 2021Article
- The Role of Tumour Metabolism in Cisplatin Resistance.Frontiers in molecular biosciences · 2021Review
- Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto's Thyroiditis.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to explore the expression of phosphoinositide-dependent protein kinase 1 (PDK-1), deleted in malignant brain tumors (DMBT1) in the thyroid carcinoma. A total of 87 fresh samples of thyroid carcinoma from surgical resection in The Second People's Hospital of Lianyungang from June 2016 to March 2018 were collected for the ELISA to detect the protein expression of PDK-1 and DMBT1. Then the pathological significance of the expression of PDK-1 and DMBT1 in the thyroid carcinoma and the correlation between them were analyzed, using the ROC curve to study the diagnostic value of each index. The expression of PDK-1 in the thyroid carcinoma tissue was significantly higher than that in the normal thyroid tissue with a statistical difference between them (P<0.05); the expression of DMBT1 in the thyroid carcinoma was statistically significantly lower than that in the normal thyroid tissue (P<0.05); the PDK-1 and DMBT1 expressions were in negative correlation in the thyroid carcinoma (r=-0.889, P<0.001). The AUG, specificity and the sensitivity of the PDK-1 in diagnosing the thyroid carcinoma were 0.862, 86.21% and 78.16%, respectively; the AUG, specificity and the sensitivity of the DMBT1 in diagnosing the thyroid carcinoma were 0.708, 66.67% and 67.82%, respectively; while the AUG, the specificity and the sensitivity of the combination of PDK-1 and DMBT1 in diagnosing the thyroid carcinoma were 0.888, 89.66% and 81.61%. In conclusion, the occurrence and progression of the thyroid carcinoma were related to the high expression of the PDK-1 and the low expression of the DMBT1 in the thyroid carcinoma tissues, the two of which were in connection with factors involving lymph node metastasis, pathological type, neoplasm staging, and clinical staging. Thus, the combined detection of PDK-1 and DMBT1 could be used as an effective index to determine the occurrence of thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.